Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull: Case report

Journal of Neurosurgery

Volumn 109, Issue 5, 2008, Pages 889-892

  Chao, Kevin ^a   Katznelson, Laurence ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Alendronate; Bisphosphonate; Fibrous dysplasia; Palliation; Skull

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; NARCOTIC ANALGESIC AGENT; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FIBROUS DYSPLASIA; FOLLOW UP; HEADACHE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKULL; SUBSTERNAL PAIN; TREATMENT DURATION; VISUAL ANALOG SCALE; DOSE RESPONSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROUS DYSPLASIA OF BONE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SKULL; TREATMENT OUTCOME;

EID: 58149166477     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS/2008/109/11/0889     Document Type: Article

References (23)

1. Chapurlat R: Current pharmacological treatment for fibrous dysplasia and perspectives for the future. Joint Bone Spine 72:196-198, 2005
2. Chapurlat RD: Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 21 (2 Suppl):P114-P119, 2006
3. Chapurlat RD, Delmas PD, Liens D, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752, 1997 (Pubitemid 27422377)
4. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ: Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35:235-242, 2004 (Pubitemid 38789170)
5. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al: Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 63:230-235, 1998 (Pubitemid 28387975)
6. Dolgitser M, Stern L, Katz LM, Doyle JJ, Omar M, Seton M, et al: Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database. Manag Care Interface 20:33-40, 2007 (Pubitemid 46411425)
7. Dumont AS, Boulos PT, Jane JA Jr, Ellegala DB, Newman SA, Jane JA Sr: Cranioorbital fibrous dysplasia: with emphasis on visual impairment and current surgical management. Neurosurg Focus 10(5):E6, 2001
8. Egner-Hobarth S, Welkerling H, Windhager R: [Bisphosphonates in the therapy of fibrous dysplasia: relevant data and practical aspects.] Orthopade 36:124-130, 2007 (Ger)
9. Glorieux FH, Rauch F: Medical therapy of children with fibrous dysplasia. J Bone Miner Res 21 (2 Suppl):P110-P113, 2006
10. Khadilkar VV, Khadilkar AV, Maskati GB: Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr 40:894-896, 2003
11. Kitagawa Y, Tamai K, Ito H: Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci 9:521-525, 2004 (Pubitemid 39410183)
12. Kumar S: Bisphosphonate therapy in polyostotic fibrous dysplasia. Indian Pediatr 41:1069-1070, 2004
13. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider R, et al: Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 382:6-12, 2001 (Pubitemid 32047423)
14. Liens D, Delmas PD, Meunier PJ: Long-term effects of intrave nous pamidronate in fibrous dysplasia of bone. Lancet 343:953-954, 1994 (Pubitemid 24117233)
15. Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423, 2007 (Pubitemid 46343586)
16. Parisi MS, Oliveri B, Mautalen CA: Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33:582-588, 2003 (Pubitemid 37222384)
17. Reszka AA, Rodan GA: Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1:45-52, 2003
18. Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Gehron Robey P: Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 33:434-442, 2003 (Pubitemid 37103260)
19. Riminucci M, Saggio I, Robey PG, Bianco P: Fibrous dysplasia as a stem cell disease. J Bone Miner Res 21 (2 Suppl):P125-P131, 2006
20. Schwartz DT, Alpert M: The malignant transformation of fibrous dysplasia. Am J Med Sci 247:1-20, 1964
21. Stanton RP: Surgery for fibrous dysplasia. J Bone Miner Res 21 (2 Suppl):P105-P109, 2006
22. sα mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 21 (2 Suppl):P120-P124, 2006
23. Yamada N, Tatsuno I: [McCune-Albright syndrome.] Nippon Rinsho Suppl 2 Suppl:126-130, 2006 (Jpn)